Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 318

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes

Eddy, David M., Schlessinger, Leonard, Kahn, Richard · 2005 · Annals of Internal Medicine

Abstract

BACKGROUND: Lifestyle modification can forestall diabetes in high-risk people, but the long-term cost-effectiveness is uncertain. OBJECTIVE: To estimate the effects of the lifestyle modification program used in the Diabetes Prevention Program (DPP) on health and economic outcomes. DESIGN: Cost-effectiveness analysis using the Archimedes model. DATA SOURCES: Published basic and epidemiologic studies, clinical trials, and Kaiser Permanente administrative data. TARGET POPULATION: Adults at high risk for diabetes (body mass index >24 kg/m2, fasting plasma glucose level of 5.2725 to 6.9375 mmol/L [95 to 125 mg/dL], 2-hour glucose tolerance test result of 7.77 to 11.0445 mmol/L [140 to 199 mg/dL]). TIME HORIZON: 5 to 30 years. PERSPECTIVE: Patient, health plan, and societal. INTERVENTIONS: No prevention, DPP's lifestyle modification program, lifestyle modification begun after a person develops diabetes, and metformin. MEASUREMENTS: Diagnosis and complications of diabetes. RESULTS OF BASE-CASE ANALYSIS: Compared with no prevention program, the DPP lifestyle program would reduce a high-risk person's 30-year chances of getting diabetes from about 72% to 61%, the chances of a serious complication from about 38% to 30%, and the chances of dying of a complication of diabetes from about 13.5% to 11.2%. Metformin would deliver about one third the long-term health benefits achievable by immediate lifestyle modification. Compared with not implementing any prevention program, the expected 30-year cost/quality-adjusted life-year (QALY) of the DPP lifestyle intervention from the health plan's perspective would be about 143,000 dollars. From a societal perspective, the cost/QALY of the lifestyle intervention compared with doing nothing would be about 62,600 dollars. Either using metformin or delaying the lifestyle intervention until after a person develops diabetes would be more cost-effective, costing about 35,400 dollars or 24,500 dollars per QALY gained, respectively, compared with no program. Compared with delaying the lifestyle program until after diabetes is diagnosed, the marginal cost-effectiveness of beginning the DPP lifestyle program immediately would be about 201,800 dollars. RESULTS OF SENSITIVITY ANALYSIS: Variability and uncertainty deriving from the structure of the model were tested by comparing the model's results with the results of real clinical trials of diabetes and its complications. The most critical element of uncertainty is the effectiveness of the lifestyle program, as expressed by the 95% CI of the DPP study. The most important potentially controllable factor is the cost of the lifestyle program. Compared with no program, lifestyle modification for high-risk people can be made cost-saving over 30 years if the annual cost of the intervention can be reduced to about 100 dollars. LIMITATIONS: Results depend on the accuracy of the model. CONCLUSIONS: Lifestyle modification is likely to have important effects on the morbidity and mortality of diabetes and should be recommended to all high-risk people. The program used in the DPP study may be too expensive for health plans or a national program to implement. Less expensive methods are needed to achieve the degree of weight loss seen in the DPP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-143-4-200508160-00006

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 318

Metadata

Authors
Eddy, D. M., Schlessinger, L., & Kahn, R.
Venue
Annals of Internal Medicine
Published
2005-08-16
Volume
143
Issue
4
Pages
251-264
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2002033855
Cited by
318
References
45
FWCI
65.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes. https://app.cochat.ai/papers/10.7326/0003-4819-143-4-200508160-00006
The paper
Eddy, D. M., Schlessinger, L., & Kahn, R. (2005). Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-143-4-200508160-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.